• In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade and Bayer partner together to help raise awareness about an available treatment option for moderate to severe hot flashes due to menopause
• Lynkuet^® (elinzanetant) 60mg capsules is an FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause
• The direct-to-consumer campaign will be shared across digital channels and streaming services, encouraging women with moderate to severe hot flashes due to menopause who are seeking hot flash relief to have an open and honest conversation with their healthcare provider about treatment options

WHIPPANY, N.J. -- (Business Wire)

Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash experiences and learn about treatment options, including Lynkuet^® (elinzanetant) 60mg capsules, a hormone-free prescription treatment for moderate to severe hot flashes due to menopause that was approved by the FDA in October 2025.¹ In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade brings this message to life by sharing her own experience with moderate to severe hot flashes, reinforcing that women with hot flashes due to menopause aren’t alone.

“When my severe hot flashes hit, they are sometimes disruptive; they can show up before big TV appearances, time with the kids, even at night,” shared Gabrielle Union-Wade. “We talk about everything, so why does talking about menopause sometimes feel taboo? I’m partnering with Bayer on the ‘Life Doesn’t Stop for a Hot Flash’ campaign because I want to use my voice for things that matter, like menopause. To me, it’s all about being honest, helping women know there are treatment options for moderate to severe hot flashes due to menopause and emphasizing something I’ve learned since entering menopause: we need to talk about this!”

Hot flashes are a common symptom of menopause² that impact women differently;³ they can be disruptive if they are severe.⁴ It’s important for women to speak with their healthcare provider openly and honestly about their symptoms. Coming prepared to an appointment with a list of questions and notes about the frequency and intensity of hot flashes can help inform the conversation and any discussion around potential treatments.

“Every woman should feel supported when discussing her hot flash experience with her healthcare provider and identifying a treatment option that is right for her,” explained Dr. Diana Bitner, OB/GYN and Chief Medical Officer and Co-Founder of True Women’s Health. “In my practice, when patients feel heard and have access to options, it makes all the difference.”

“As a global leader in women’s healthcare, Bayer is proud of our partnership with Gabrielle to raise awareness about moderate to severe hot flashes due to menopause and encourage women to talk to their healthcare provider about treatment options,” acknowledged Amy Hessels, Vice President, Women’s Healthcare Marketing at Bayer. “For women in menopause seeking hot flash relief, it’s vital they have the resources and support needed to find the treatment that’s right for them, and this campaign represents our efforts to drive this important conversation forward.”

To learn more about the campaign and to access the Lynkuet discussion guide for tips on discussing moderate to severe hot flashes due to menopause with your healthcare provider, visit lynkuet.com.

INDICATION

What is LYNKUET^® (elinzanetant)?

LYNKUET is a prescription medicine used to reduce moderate to severe hot flashes (also known as vasomotor symptoms) due to menopause. LYNKUET is not a hormone. Hot flashes are feelings of warmth in the face, neck, and chest, or sudden intense feelings of heat and sweating.

IMPORTANT SAFETY INFORMATION

Do not take LYNKUET if you:

• are pregnant

Before you use LYNKUET, tell your healthcare provider about all of your medical conditions, including if you:

• have liver problems
• have a history of seizures
• are pregnant or planning to become pregnant. LYNKUET may harm your unborn baby. Women who can become pregnant should talk to their healthcare provider to exclude pregnancy before starting treatment with LYNKUET and use effective birth control during and for 2 weeks after stopping treatment.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. LYNKUET may affect the way other medicines work, and other medicines may affect how LYNKUET works.

What should I avoid while taking LYNKUET?

• Avoid eating grapefruit or drinking grapefruit juice during treatment with LYNKUET.
• LYNKUET may cause you to feel drowsy, if you experience this avoid driving and other hazardous activities until these effects go away.

LYNKUET can cause serious side effects, including:

• Central nervous system (CNS) effects and daytime impairment. LYNKUET can cause difficulty staying awake (somnolence) and other nervous system effects including fatigue, having a spinning feeling (vertigo), dizziness, and feeling faint (presyncope). If you experience these effects, you should not drive or do hazardous activities until these effects go away.
• Increased liver blood test values. LYNKUET may cause increased liver enzymes. Your healthcare provider will do a blood test to check your liver before you start and 3 months after taking LYNKUET. Stop taking LYNKUET and tell your healthcare provider right away if you have the following signs or symptoms that suggest liver problems:
  • feeling more tired than you do usually
  • decreased appetite
  • nausea
  • vomiting
  • itching
  • yellowing of the eyes or skin (jaundice)
  • pale feces
  • dark urine
  • pain in the stomach (abdomen)
• Risk of pregnancy loss. Taking LYNKUET while pregnant may cause loss of pregnancy or stillbirth. If you think you are pregnant, stop taking LYNKUET and tell your healthcare provider right away.
• Risk of seizures in people with a history of seizures. Seek medical attention right away if you have loss of consciousness or seizure.

Common side effects of LYNKUET include:

• headache
• fatigue
• dizziness
• feeling drowsy or sleepy
• stomach (abdominal) pain
• rash
• diarrhea
• muscle spasms

Tell your healthcare provider if you have any side effects that do not go away. These are not all the possible side effects of LYNKUET.

LYNKUET is available by prescription only.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

For important information about LYNKUET, please see the Full Prescribing Information.

Disclosures

Gabrielle Union-Wade is a paid Bayer spokesperson and has been compensated for her time. She is taking Lynkuet.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros.

Find more information at www.pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on X: @BayerPharma

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

References

¹LYNKUET^® (elinzanetant) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; October 2025
²Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011;38(3):489-501.
³ Shepherd JA, Shiozawa A, Schild AL, et. al. Retrospective text and qualitative analyses of patient experience and management of vasomotor symptoms due to menopause: voices from the PatientsLikeMe community. Menopause. 2024;31(9):789-795.
⁴US Food and Drug Administration. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy. FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy. Accessed October 23, 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260109371123/en/

Contacts:

Media Contact:
Jackie Zima-Evans
jackie.zima-evans@bayer.com
+1 215.534.2973

Source: Bayer